Experience of Using Amantadine Sulfate (PK-Merz) in Patients with Ischemic Stroke


ischemic stroke
amantadine sulfate
Bispectral Index

How to Cite

Gryb, V. A., Titov, I. I., Chmyr, G. S., & Khlibeychuk, G. I. (2016). Experience of Using Amantadine Sulfate (PK-Merz) in Patients with Ischemic Stroke. Galician Medical Journal, 23(3). https://doi.org/10.21802/gmj.2016.3.30


The article presents the results of combination treatment of patients with acute ischemic stroke (the NIH Stroke Scale – 12.04±0.57). The efficacy of conventional therapy (the control group) was compared with treatment regimen using amantadine sulfate (PK-Merz) (the main group). In patients undergoing combination treatment lost functions were restored quite promptly and 2 months after the observation their functional state was satisfactory (the NIH Stroke Scale: the main group – 2.49±0.78, the control group – 5.53±0.69, p=0.009); moreover, the subscale “language” differed significantly from that in patients receiving basic therapy only (р<0.05). Due to the blockade of NMDA receptors, which contributes to the reduction in the intensity of the “excitotoxicity cascade” preserving the penumbral area as well as due to the increase in dopamine concentration both by increasing the release and blocking the re-uptake in presynaptic nerve cells, the use of amantadine sulfate is a pathogenetically justified means of cerebroprotection in the acute phase of ischemic stroke. The use of PK-Merz is proven to contribute to rapid recovery of consciousness, significant regression of neurological deficit resulting in disability reduction.



Cherniy VI, Andronova IA, Gorodnik GA, Nazarenko KV. Antagonist glutamatnykh NMDA-retseptorov (amantadina sulfat) v intensivnoy terapiyi tyazheloy cherepno-mozgovoy travmy. Emergency medicine. 2015;5(68). Russian

Galushka SV, Lazarev KV. Prakticheskiye rekomendatsiyi po ispolzovaniyu BIS-monitora vo vremya anesteziyi. Available from: http://www.critical.ru/actual/anest/monitor_guide.htm. Russian

Gomazkov OA. Neurochemistry of the ischemic and age-related brain pathologies. Information & Analytical Edition. Moscow; 2003. 200 p.

Karaban IN. Use of glutamate receptor blocker amantadine in neurology. International neurological journal. 2012;2:195-201.

Kolesnikov AN, Chernutskiy SO, Stasyuk VN, Druzhinskaya EA. Opyt primeneniya antagonista glutamatnykh NMDA-retseptorov (PK-Merts) pri povrezhdeniyakh golovnogo mozga travmaticheskogo proiskhozhdeniya v ostrom periode (opisaniyeklinicheskogo sluchaya). Emergency medicine. 2014;3(58):60-65. Russian

Nikonov VV, Savitskaya IB. Role of Glutamate Receptor Antagonists (PK-Merz) in Treatment of Brain Lesions (Literature Review). Emergency medicine. 2012;5(44):36-40.

Dziak LA, Zozulia OO, Klyhunenko OM, Kusch YeA. New features of multimodal pharmacotherapy of acute ischemic stroke. International neurological journal. 2015;5(75):39-44.

Culebras A, et al. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology. 2004;62:1073-1080. http://dx.doi.org/10.1212/01.WNL.0000113757.34662.AA

Ekman A, Lindholm ML, Lennmarken C. Reduction in the Incidence of Awareness Using BIS Monitoring. Acta Anaesthesiol Scand. 2004;48(1):20-26. http://dx.doi.org/10.1111/j.1399-6576.2004.00260.x

Faden AI, Stoica B. Neuroprotection: challenges and opportunities [review]. Arch Neurol. 2007;64:794-800. http://dx.doi.org/10.1001/archneur.64.6.794

Internet Stroke Center. Available from: http://www.strokecenter.org/trials/index_cats.aspx

Reis J, et al. Modulation of human motor cortex excitability by single doses of amantadine. Neuropsychopharmacology. 2006;31:12. http://dx.doi.org/10.1038/sj.npp.1301122

Hammond FM, et al. Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression. J Head Trauma Rehabil. 2014;29(5):391-399. http://dx.doi.org/10.1097/01.HTR.0000438116.56228.de

Saver JL. Time is brain – quantified. Stroke. 2006;37:263-266. http://dx.doi.org/10.1161/01.STR.0000196957.55928.ab

Thomas A, Bonnani L, Gambi F. Pathological gambling in Parkinson's disease is reduced by amantadine. Ann Neurol. 2010;68:400-404. http://dx.doi.org/10.1002/ana.22029

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.